Identification of an HLA-DPB1*0501 Restricted Melan-A/MART-1 Epitope Recognized by CD4 + T Lymphocytes: Prevalence for Immunotherapy in Asian Populations

Journal of Immunotherapy

Volumn 34, Issue 7, 2011, Pages 525-534

  Meng, Zhaoting ^a,b   Wang, Yadong ^c   Zhang, Guanzhong ^a   Ke, Yuehua ^d   Yan, Yanfeng ^d   Wu, Liangliang ^a   Huang, Qianrong ^c   Zeng, Gang ^e   Wang, Yu ^c   Ying, Han ^c   Jiao, Shunchang ^a  

^a PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

^c Immunntech Applied Science Limited   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD4 + T cells; HLA DPB1*0501; Melan A MART 1; melanoma; Tumor immunotherapy

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DPB1 ANTIGEN; HLA DQ ANTIGEN; HLA DR1 ANTIGEN; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; MELAN A;

ANTIGEN RECOGNITION; ARTICLE; ASIAN; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MELANOCYTE; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; TUMOR CELL;

ANTIGENS, NEOPLASM; ASIAN CONTINENTAL ANCESTRY GROUP; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY TESTING; HLA-DP BETA-CHAINS; HUMANS; IMMUNOTHERAPY; MART-1 ANTIGEN; MELANOCYTES; MELANOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80051548608     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318226bd45     Document Type: Article

References (40)

1. Homsi J, Grimm JC, Hwu P. Immunotherapy of melanoma: an update. Surg Oncol Clin N Am. 2011;20:145-163.
2. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009;21:200-208.
3. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637-650.
4. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001;22:269-276.
5. Haigh TA, Lin X, Jia H, et al. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol. 2008;180:1643-1654.
6. Guo Y, Niiya H, Azuma T, et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood. 2005;106:1415-1418. (Pubitemid 41129609)
7. Livingstone AM, Wilson EB, Ontiveros F, et al. Unravelling the mechanisms of help for CD8+ T cell responses. Immunol Res. 2009.
8. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10:248-256.
9. Canderan G, Dellabona P. T helper 17 T cells do good for cancer immunotherapy. Immunotherapy. 2010;2:21-24.
10. Kmieciak M, Worschech A, Nikizad H, et al. CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res Treat. 2011;126:385-394.
11. Kennedy R, Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol. 2006;177:2862-2872. (Pubitemid 44277801)
12. Rocha B, Tanchot C. Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr Opin Immunol. 2004;16:259-263. (Pubitemid 38595362)
13. Kennedy R, Undale AH, Kieper WC, et al. Direct crosspriming by th lymphocytes generates memory cytotoxic T cell responses. J Immunol. 2005;174:3967-3977. (Pubitemid 40395971)
14. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358:2698-2703. (Pubitemid 351860862)
15. Xie Y, Akpinarli A, Maris C, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010;207:651-667.
16. Hofbauer GF, Kamarashev J, Geertsen R, et al. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998;8:337-343. (Pubitemid 28442565)
17. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J ExpMed. 1994;180:35-42. (Pubitemid 24181053)
18. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180:347-352. (Pubitemid 24181083)
19. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med. 1995;181:363-368.
20. Schneider J, Brichard V, Boon T, et al. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer. 1998;75: 451-458. (Pubitemid 28100050)
21. Benlalam H, Linard B, Guilloux Y, et al. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003;171:6283-6289. (Pubitemid 37467252)
22. Larrieu P, Renaud V, Godet Y, et al. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes. Cancer Immunol Immunother. 2008;57:745-752.
23. Bioley G, Jandus C, Tuyaerts S, et al. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006;177:6769-6779. (Pubitemid 44715041)
24. Depontieu FR, Qian J, Zarling AL, et al. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci USA. 2009;106:12073-12078.
25. Zarour HM, Kirkwood JM, Kierstead LS, et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA. 2000;97:400-405. (Pubitemid 30055843)
26. Godefroy E, Scotto L, Souleimanian NE, et al. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol. 2006;121:54-62. (Pubitemid 44389962)
27. Yamasaki K, Horiuchi I, Minohara M, et al. HLADPB1* 0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain. 1999;122(Pt 9):1689-1696. (Pubitemid 29425672)
28. Godefroy E, Wang Y, Souleimanian NE, et al. Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancerfree individuals. Cancer Immunol Immunother. 2007;56: 1183-1192. (Pubitemid 46763933)
29. Chen YT, Stockert E, Jungbluth A, et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA. 1996;93:5915-5919. (Pubitemid 26191318)
30. Ayyoub M, Stevanovic S, Sahin U, et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumorreactive CTL infiltrating metastatic melanoma. J Immunol. 2002;168:1717-1722. (Pubitemid 34135769)
31. Ayyoub M, Hesdorffer CS, Montes M, et al. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest. 2004;113:1225-1233. (Pubitemid 38544108)
32. Neumann F, Wagner C, Stevanovic S, et al. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOMMEL-40/SSX2. Int J Cancer. 2004;112:661-668. (Pubitemid 39425947)
33. Ayyoub M, Merlo A, Hesdorffer CS, et al. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin Immunol. 2005;114:70-78. (Pubitemid 39642792)
34. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265-270. (Pubitemid 28060443)
35. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NYESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000;165:948-955. (Pubitemid 30484763)
36. Valmori D, Dutoit V, Lienard D, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000;60:4499-4506. (Pubitemid 32103631)
37. Zeng G, Wang X, Robbins PF, et al. CD4(+) T cell recognition of MHC class II-restricted epitopes from NYESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA. 2001;98:3964-3969. (Pubitemid 32249881)
38. Brown SA, Stambas J, Zhan X, et al. Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity. J Immunol. 2003;171:4140-4148. (Pubitemid 37238690)
39. Gupta V, Tabiin TM, Sun K, et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNAencoded immunogens. Virology. 2006;347:127-139.
40. Zhang GL, Khan AM, Srinivasan KN, et al. Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes. BMC Bioinformatics. 2008;9(Suppl 1):S19.